With the rapid onset of game-changing injectable emicizumab [HEMLIBRA] therapy for hemophilia, coagulation laboratories face a new challenge. On the occasions when HEMLIBRA-treated hemophiliacs need factor VIII concentrate therapy, or if there is a desire to test for residual factor VIII, what means does the laboratory possess? Likewise, the clinician may need a means to check for a factor VIII inhibitor, what is available? Please look to the right for our April, 2020 Quick Question, “How does your facility measure factor VIII during HEMLIBRA therapy?” Select your answer and please provide us with detailed information on your facility’s approach, using the Comments section below.
[Many thanks to Dr; Ali Sadeghi-Khomami for his comprehensive April 4, 2020 comment below.]